Biotech | February 25, 2022
Biohaven licenses Taldefgrobep Alfa from Bristol Myers Squibb
It is a Phase 3 ready anti-myostatin adnectin for Spinal Muscular Atrophy (SMA).
It is a Phase 3 ready anti-myostatin adnectin for Spinal Muscular Atrophy (SMA).
The recently released WHO guideline on hypertension treatment (2021), recommends that patients with stable blood pressure can be asked to visit clinics at 3-6 month intervals as an important strategy to improve hypertension control
Cataract is the most common cause of blindness in India, and that diabetes is to be blamed for the massive number of damaged eyes
Collaboration in the industry needs to be institutionalised to drive the growth.
The drug will be manufactured at the group's formulation manufacturing facility at the SEZ, Ahmedabad
Adds to Merck’s growing global, multi-modality CDMO network, following newly formed CDMO business unit in Life Science
Robust pipeline with around 50 projects in clinical development / cardiology portfolio poised for growth with launch products Kerendia (finerenone) and Verquvo (vericiguat)
AIIA partners with Startup India with the aim to identify and support innovations and start-ups working in the Ayush sector
The COVID-19 pandemic has triggered the rapid growth of the biotherapeutics market
Essential products manufactured by Sartorius, using Sü dpack polymer films made from Dow resins, support safe and effective vaccine production for global vaccine supply
Subscribe To Our Newsletter & Stay Updated
